Main menu

Cancer Research and Publish- Oncontarget

Ample research has been done conducted o the courses, prevention, and the treatment of cancer. Scholars and medical professionals have also written books on cancer as is a major crisis in the world. Oncotarget is one of the journals that publishes research papers on cancer and oncology. Since its establishment, the journal has expanded, and due to the development of tumor and the personal integrity, the journal has extended its publish to other fields including, pathology, physiology, endocrinology, age-related diseases, and immunology.

Oncotarget was established in 2010. The Journal, have experienced chief editors led by Andrei Gudkov, and Mikhail Blagosklonny who work at Roswell Park Institute. The weekly journal is usually released online, and the management has made a free to enable for quick research and rapid viewing of the articles. The papers are mostly published on DovePress.com. According to reports released by Thomson Reuters, Oncotarget has been rated number one since 2011 to date. View Mikhail’s profile on Google Scholar.

The journal has been going through a line of success since its inception, and it has made its articles available on other media platforms including Facebook, Twitter, Google, Linked, and YouTube in efforts of reaching more audience. The journal has editors who mainly do the editing of the articles sent by different authors. To be an editor at Oncotarget one needs to be qualified for authorship. After the papers have been written, they have to pass through the editors for verification and correction before being forwarded to the chief editors who decides if the articles will be published on their page.

Writing medical articles on onto target has an added advantage to the authors as they can be able to see the progress of their articles before they are published. Oncotarget has also posted on different researchers including the relationship between E-cigarette and gum tissue. The research was done on more than 320 individuals showed that more than 260 patients who were treated with platinum chemotherapy, and fluoropyrimidine had better chances of survival. Oncotarget requires that all research was done and s to be published on their site be approved by the authors’ institutional review board or equivalent committee.